PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-27.41%
Both companies show declining cash positions (-27.41% vs TRAW's -38.74%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-27.41%
Cash + STI yoy 0.5-0.75x TRAW's -38.74%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.07%
Other current assets growth < half of TRAW's 50.00%. David Dodd sees a leaner approach to short-term items.
-28.37%
0.75-0.9x TRAW's -37.01%. Bill Ackman would ask if competitor is building short-term resources more aggressively.
1187.39%
Below half TRAW's -88.89%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Less than half of TRAW's 0.67%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
252.00%
Below half of TRAW's -4.43%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Below half of TRAW's -36.72%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-8.53%
Less than half of TRAW's 7.30%. David Dodd sees a more disciplined AP approach or lower volume.
-29.62%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
12.29%
Higher Deferred Revenue (Current) Growth compared to TRAW's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-3.44%
Above 1.5x TRAW's -0.34%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7668.72%
Above 1.5x TRAW's 9.03%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
13.42%
Above 1.5x TRAW's 2.72%. Michael Burry sees a potential leverage warning sign.
2.97%
Similar yoy changes to TRAW's 3.51%. Walter Schloss sees parallel capital-raising strategies.
-3.03%
≥ 1.5x TRAW's -1.99%. David Dodd sees higher yoy retained profits than competitor.
25.83%
Less than half of TRAW's -50.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-39.38%
Below half TRAW's -128.51%. Michael Burry sees potential underperformance in building shareholder capital.
-17.83%
Below half TRAW's -36.72%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
499.58%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
37.73%
Similar yoy changes to TRAW's 38.74%. Walter Schloss sees parallel net leverage strategies.